Aptitude has received multi-million dollars in funding in 2021.
Aptitude and Google jointly published machine learning-guided aptamer research on Nature Communications
Aptitude received California CLIA license for high-complexity molecular testing
Aptitude was admitted into the prestigious NIH RADx program
Aptitude has received multi-million dollars in funding in 2019.
Aptitude has received EPO approval of our patent application on the breakthrough Particle Display technology.
Aptitude has successfully demonstrated the efficacy advantage of our bispecific aptamer over standard anti-VEGF agents in collaboration with researchers at the Johns Hopkins University.
Aptitude has received multi-million dollars in funding in 2018.
Aptitude has received USPTO approval of our patent application on the breakthrough Particle Display technology.
Aptitude has launched a bispecific therapeutic program which leverages the unique physicochemical properties of aptamers to achieve the effect of combination therapy with a single agent.
Aptitude has launched the third aptamer therapeutic program in collaboration with researchers at the Johns Hopkins University
Aptitude has successfully demonstrated the in vivo efficacy of the second aptamer program in preclinical animal models, in collaboration with researchers from Bascom Palmer Eye Institute.
Aptitude has received ~5 million dollars in non-dilutive funding.
Aptitude has entered into a collaboration with a global leader in clinical diagnostics, who is interested in leveraging aptamers’ unique properties to address unmet needs in diagnostics.
Aptitude scientists published a paper in Angewandte Chemie, reporting unprecedented aptamer specificity and superior performance to commercial antibody product, enabled by our proprietary Multi-Parameter Particle Display technology.
Aptitude has successfully demonstrated the in vivo efficacy and safety of our first therapeutic aptamer program in two different preclinical animal models.
Aptitude has completed the in vitro discovery of our first fully-modified therapeutic aptamer. The lead aptamer demonstrates pM level affinity, high specificity against homolog proteins, and high potency in blocking target signaling.
Aptitude has initiated collaboration with a major tech company, applying state-of-the-art Particle Display and machine learning technologies toward unlocking new levels of performance and throughput in our Aptamer discovery capabilities.
Aptitude has further expanded the capability of Particle Display to uniquely develop fully modified aptamers, which possess optimal in vivo stability for therapeutic applications.
Aptitude has been awarded a contract from the DoD to develop a hand-held device for rapid field diagnosis of vital conditions.
Aptitude has made a major technical breakthrough, which integrates a wide range of modified nucleobases into our proprietary Particle Display technology. By combining Partile Display with non-natural nucleotides, Aptitude can harness greatly expanded chemical diversity to enable improved affinity, specificity and success rate.
Aptitude has been awarded a contract by a top pharma company to develop a drug R&D tool for which antibodies are not able to meet the performance requirement.
Aptitude has developed Multi-Parameter Particle Display, enabling simultaneous quantitative measurement of the affinity, specificity, and other desired properties of each aptamer candidate.
Aptitude’s progress has been highlighted by Congresswoman Lois Capps.
Aptitude has initiated a collaboration with a top diagnostic company to exploit the unique properties of aptamers for applications at the point of care.
Aptitude is awarded a prestigious Fast-Track SBIR Grant from the NIH. Among the ~4000 companies that apply to SBIR/STTR grants every year, only ~40 companies with the most validated technology are awarded a Fast-Track grant.
Aptitude scientists published breakthrough Particle Display technology in Angewandte Chemie.